%0 Journal Article %T Clinical utility of fixed-combination telmisartan¨Camlodipine in the treatment of hypertension %A Segura J %A Ruilope LM %J Integrated Blood Pressure Control %D 2011 %I Dove Medical Press %R http://dx.doi.org/10.2147/IBPC.S9934 %X ical utility of fixed-combination telmisartan¨Camlodipine in the treatment of hypertension Review (4424) Total Article Views Authors: Segura J, Ruilope LM Published Date May 2011 Volume 2011:4 Pages 27 - 34 DOI: http://dx.doi.org/10.2147/IBPC.S9934 Julian Segura, Luis M Ruilope Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain Abstract: The majority of hypertensive patients, especially those with target organ damage, are likely to require multiple-drug therapy in order to reach blood pressure (BP) targets and reduce their risk of adverse vascular outcomes. The rationale for combination therapy with agents that block the renin¨Cangiotensin system (RAS) and a calcium channel blocker (CCB) or diuretic is well founded in growing evidence. Recent published trials have shown that the combination of an RAS suppressor and a dihydropiridinic CCB would offer additional benefits independently of BP reduction. A telmisartan¨Camlodipine combination has demonstrated significantly greater BP reductions compared with each monotherapy component in the overall population, and in particular in patients with moderate to severe hypertension and high-risk patients. This combination is well tolerated with a safety profile similar to placebo and is consistent with the known safety profile of its monotherapy components. %K hypertensive patients %K monotherapy %K stroke %K antihypertensive %U https://www.dovepress.com/clinical-utility-of-fixed-combination-telmisartanndashamlodipine-in-th-peer-reviewed-article-IBPC